Search research articles
Contact Us
Filters
Showing results (11-20 of 330) with videos related to
Page
of 33
Sort By:
Oncotarget
|
November 9, 2017
Molecular response prediction in CML: novel ideas?
Dominik Wolf, Sieghart Sopper
Expert Review of Hematology
|
April 19, 2011
Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
Jakob Rudzki, Dominik Wolf
Cancer Immunology Research
|
April 1, 2022
IFNγ Helps CBLB-Deficient CD8+ T Cells to Put Up Resistance to Tregs
Dominik Wolf, Gottfried Baier
Drug Safety
|
October 9, 2009
A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours
Dominik Wolf, Holger Rumpold
International Journal of Cancer
|
October 15, 2020
Vaccination influenz(a)ing cancer-specific survival
Dominik Wolf, Andreas Pircher
Frontiers in Oncology
|
November 17, 2022
Editorial: Current innovations in GI-oncology: Where do we stand?
Holger Rumpold, Dominik Wolf
European Journal of Haematology
|
August 25, 2015
When and how to 'FLAMSA-RIC' in acute myeloid leukemia?
Dominik Wolf, Karin Mayer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2015
CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies--Immuno-oncology Advances Clinical Cancer Research
Dominik Wolf, Anna Maria Wolf
Lancet (London, England)
|
May 13, 2008
Mesenchymal stem cells as cellular immunosuppressants
Dominik Wolf, Anna Maria Wolf
Circulation
|
May 25, 2005
Letters regarding article by Wojakowski et al, "mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction"
Dominik Wolf, Holger Rumpold, Eberhard Gunsilius
Page
of 33
Search research articles
Search
Showing results (11-20 of 330) with videos related to
Sort By:
Page
of 33
Oncotarget
|
November 9, 2017
Molecular response prediction in CML: novel ideas?
Dominik Wolf, Sieghart Sopper
Expert Review of Hematology
|
April 19, 2011
Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
Jakob Rudzki, Dominik Wolf
Cancer Immunology Research
|
April 1, 2022
IFNγ Helps CBLB-Deficient CD8+ T Cells to Put Up Resistance to Tregs
Dominik Wolf, Gottfried Baier
Drug Safety
|
October 9, 2009
A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours
Dominik Wolf, Holger Rumpold
International Journal of Cancer
|
October 15, 2020
Vaccination influenz(a)ing cancer-specific survival
Dominik Wolf, Andreas Pircher
Frontiers in Oncology
|
November 17, 2022
Editorial: Current innovations in GI-oncology: Where do we stand?
Holger Rumpold, Dominik Wolf
European Journal of Haematology
|
August 25, 2015
When and how to 'FLAMSA-RIC' in acute myeloid leukemia?
Dominik Wolf, Karin Mayer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2015
CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies--Immuno-oncology Advances Clinical Cancer Research
Dominik Wolf, Anna Maria Wolf
Lancet (London, England)
|
May 13, 2008
Mesenchymal stem cells as cellular immunosuppressants
Dominik Wolf, Anna Maria Wolf
Circulation
|
May 25, 2005
Letters regarding article by Wojakowski et al, "mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction"
Dominik Wolf, Holger Rumpold, Eberhard Gunsilius
Page
of 33